Deals in Depth: November 2008
Executive Summary
November 2008 dealmaking highlights: Genzyme's deal for Osiris's stem cell therapeutics Prochymal and Chondrogen topped the alliance list at a pre-commercial value of $730mm, one of the highest this year. J&J's acquisition of biomaterials company Omrix for $438mm was the highest-valued acquisition, outdoing the pharma group M&As, the leaders of which barely reached $50mm. Money invested in pharma increased slightly and again early and late VC dominated; and device financings took a nosedive, decreasing 81% from last month, and mostly comprised of debt.